Drug Database
Back to search

Netherlands· NL-f2129f7a2796

Olumiant 2 mg, filmomhulde tabletten

A selective immunosuppressants product containing baricitinib, registered in Netherlands by Eli Lilly Nederland B.V.. The same ATC class is registered in 5 of our 19 countries.

ATC L04AA

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedOlumiant 2 mg, filmomhulde tablettenATCL04AAREGISTER NO.NL-f2129f7a2796PACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about baricitinibAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Baricitinib is registered in 5 of 19 countries.

Countries holding a registration under ATC L04AA (selective immunosuppressants), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 2 of them publish a price we can compare per daily dose
Search baricitinib products by name

Baricitinib · ATC L04AA

5 / 19 countries

  • Denmark
  • Icelandprice
  • Ireland
  • Netherlands
  • Polandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
BARICITINIB
Manufacturer
Eli Lilly Nederland B.V.
Country
Netherlands (NL)
ATC code
L04AA
ATC class
Selective immunosuppressants
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/16/1170

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Baricitinib in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All baricitinib products

Authorised across Europe · EMA

The same active substance is authorised in 4 EEA countries. Names it is sold under:

  • Iceland · Olumiant
  • Liechtenstein · Olumiant
  • Norway · Olumiant
  • Portugal · Baricitinib Generis

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/6267d4e7-464c-47d8-96b4-427737d7421e
GET /v1/drugs/6267d4e7-464c-47d8-96b4-427737d7421e?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Filmomhulde tablet",
  "route": "Oraal gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/olumiant-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Selective Immunosuppressants",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp118792",
  "excipients": [
    "CELLULOSE, MICROKRISTALLIJN (E 460(i))",
    "CROSCARMELLOSE  NATRIUM  (E 468)",
    "IJZEROXIDE ROOD  (E 172)",
    "LECITHINE, SOYA (E 322)",
    "MACROGOL 4000",
    "MAGNESIUMSTEARAAT (E 470b)",
    "MANNITOL (D-) (E 421)",
    "POLYVINYLALCOHOL, GEDEELTELIJK GEHYDROLYSEERD (E1203)",
    "TALK (E 553b)",
    "TITAANDIOXIDE (E 171)"
  ],
  "substances": [
    "BARICITINIB"
  ],
  "leaflet_url": null,
  "authorised_at": "2017/02/13",
  "procedure_number": "EMEA/H/C/004085",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/16/1170",
  "additional_monitoring": "N"
}
API referenceMCP serverPlans

See everything about baricitinib.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console